<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints
Image Overlay - Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

October 16, 2020

Exogenesis COVID-19 Deactivation Challenge Trial Reaches Primary Endpoints

Exogenesis Corporation announced that it had acheived the primary endpoints of trapping and deactivating SARS-CoV-2 in simulated real-world exposures in a series of challenge tests for the Exogenesis Surgical Mask (ESM), a protective nose and mouth covering for healthcare workers and patients involved in medical and surgical procedures. Any innovation that enhances patient and clinician safety is welcome news to Yourway and our clients trying to conduct clinical trials during the pandemic.

 Back to Index
Media

Upcoming Events

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?